AnalystsInsight

Kallum Titchmarsh (Morgan Stanley): Analyst Track Record and Price‑Target Accuracy

How often Kallum Titchmarsh’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 544 ratings, compared with the average Wall Street analyst.

Reviewed by:David, Senior AnalystPublished Nov 9, 2026Updated Nov 9, 20263 min readHow we research

Key takeaways

Kallum Titchmarsh ranks #994 of 1,181 analysts in Exent’s scoring (4.6★).
74.0% of price targets were reached over 7 years, versus 53.1% for the average analyst.
Median time to reach a target: 54 days; 52.8% of calls were up 12 months later.
Most‑covered stocks: STVN, WST, GH, CRL.
Free on Exent: Kallum Titchmarsh’s full record, with ratings 3 days after publication.

Which stocks do Wall Street’s best‑ranked analysts agree on? See them in Exent Gems →

In this article

Kallum Titchmarsh’s track record at a glance
How fast price targets were reached
Stocks Kallum Titchmarsh covers most
Exent’s top 50 analysts
Kallum Titchmarsh’s latest ratings
More analysts to compare
How Exent scores analysts

Kallum Titchmarsh’s track record at a glance

Kallum Titchmarsh of Morgan Stanley ranks #994 of the 1,181 analysts Exent scores, with a 4.6★ rating and a focus on healthcare. Over a 7‑year lookback, 74.0% of Kallum’s price targets were reached, 20.9 points above the 53.1% average across all analysts.

Metric	Kallum Titchmarsh	All analysts
Price‑target hit rate	74.0%	53.1%
Median days to hit target	54 days	93 days
Calls up after 12 months	52.8%	64.4%
Median 12‑month return of calls	+7.0%	+13.5%
Hit rate, last 2 years	74.6%	—
Average worst drop after a call	−26.0%	—
Ratings in the sample	544	—
Stocks covered	31	—

The full records of Exent’s top 50 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

See the top-ranked analysts in Gems

How fast price targets were reached

Time to reach the target	Kallum Titchmarsh
Under 30 days	33.3%
30–90 days	31.5%
90–180 days	15.0%
Over 180 days	20.3%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Kallum Titchmarsh covers most

Stock	Ratings in the sample
STVN	34
WST	24
GH	22
CRL	21
GRAL	21
DHR	19
A	18
NTRA	18

In the past year Kallum’s ratings were 40% Buy, 55% Hold and 5% Sell.

Exent’s top 50 analysts

Across 983,543 ratings, the average Wall Street analyst’s price target was reached 53.1% of the time: close to a coin flip. The spread between analysts is wide, and 14.3% of the 965 analysts with a measurable record reached 70% or more (Exent data, Nov 9, 2026).

Exent Gems is built on the top 50 of Exent’s ranking. Over the last two years, some of them reached 90% or more of their price targets. Who they are, which stocks they are calling now and how often they have been right is for members.

Unlock the top 50 analysts

Kallum Titchmarsh’s latest ratings

Date	Stock	Action	Rating	Price target
Oct 20, 2026	GH	Reiterated: Buy	Buy	$200.00
Oct 13, 2026	TMO	Rated: Buy	Buy	$730.00
Oct 13, 2026	A	Rated: Buy	Buy	$190.00
Oct 13, 2026	CRL	Rated: Buy	Buy	$340.00
Oct 13, 2026	GH	Rated: Buy	Buy	$200.00
Oct 13, 2026	DHR	Rated: Buy	Buy	$240.00
Oct 13, 2026	AVTR	Rated: Hold	Hold	$15.00
Oct 13, 2026	GRAL	Maintained: Hold	Hold	$120.00
Oct 13, 2026	ADPT	Reiterated: Hold	Hold	$27.00
Oct 13, 2026	NTRA	Rated: Buy	Buy	$435.00

Oct 20, 2026
Stock
GH
Action
Reiterated: Buy
Rating
Buy
Price target
$200.00
Oct 13, 2026
Stock
TMO
Action
Rated: Buy
Rating
Buy
Price target
$730.00
Oct 13, 2026
Stock
A
Action
Rated: Buy
Rating
Buy
Price target
$190.00
Oct 13, 2026
Stock
CRL
Action
Rated: Buy
Rating
Buy
Price target
$340.00
Oct 13, 2026
Stock
GH
Action
Rated: Buy
Rating
Buy
Price target
$200.00
Oct 13, 2026
Stock
DHR
Action
Rated: Buy
Rating
Buy
Price target
$240.00
Oct 13, 2026
Stock
AVTR
Action
Rated: Hold
Rating
Hold
Price target
$15.00
Oct 13, 2026
Stock
GRAL
Action
Maintained: Hold
Rating
Hold
Price target
$120.00
Oct 13, 2026
Stock
ADPT
Action
Reiterated: Hold
Rating
Hold
Price target
$27.00
Oct 13, 2026
Stock
NTRA
Action
Rated: Buy
Rating
Buy
Price target
$435.00

Kallum’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

See the top-ranked analysts in Gems

More analysts to compare

Also at Morgan Stanley: Maxwell Skor · Shane Brett CFA · Devin McDermott · Christopher Snyder · Meta Marshall · Erik Woodring

Also covering healthcare: Yanan Zhu · Madison Elsaadi · Daniel Arias · Paul Matteis · Casey Woodring · Jason Zemansky

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Nov 9, 2026; ranking updated Nov 11, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

Exent Gems shows live ratings from the top‑ranked analysts, without the 3‑day delay used on this page.
Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

See this week’s Gems

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Kallum Titchmarsh ranks #994 of 1,181 with a 4.6★ rating. 74.0% of price targets were reached over a 7-year lookback (all analysts: 53.1%), and 52.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

In Exent’s 7-year price-target backtest, 74.0% of Kallum Titchmarsh’s price targets were reached, with a median of 54 days to reach a target (all analysts: 53.1%).

Kallum Titchmarsh (Morgan Stanley) covers 31 stocks, mostly in healthcare. The most frequently rated are STVN, WST, GH, CRL, GRAL.

: .-++++=: .-=+**+-. .:=+*#*=:..::-+##*+-:. .-+**+++=:. .:::-=+**********++===++***+++*###*+=--:. .:==+*#*+-:..::-+##*+-:. :=**++=: .-=+**+-. .:=+*#*-...: . -++*+=: .:=+**+-. .:-+*#*=:..::=+##*=-:...:=***++=:. .:-=+*###*++==--:::::::...:---==+*##**++=-. .:-=+###*=-:...-+**++=: :=++*+-. :-=***=:..:-=*##+-..: :=+*++-. :=++*+=. :-=*#*+-..::=+##*=-:...-+*#*+=-. :-=+*###*+=--:. .... .::..:-=+++****=-:..::-=*#*+=-: .-=++++=. .-=+**+-...:=+##*=:.::-+##*=::. .-++++=: .-=+**=: .-=+*#+-...:-+##*=-::.:-+##*+=:. .-=++***+=-:::.. ..:-----:::::::. .:-=+*###*=-:.. :=+**++-. .-=+**+-. .:-+*##+:..:-=*##+-:..:=*#*+-:. :=+*++-. :=+**+-. .:=+*#*-...:-+*##+-:.::-+##*=-:. :=++**++-:...::::-==+++++****++===-:....:::-+*#*+==:. .-=+**+-. .:-=*##+-:.::-+##*=::.:-+##*=-:..-+#*+=:. .-++++=: .-++**=: :-=***=:..:-=*##+-:.::-+##*=-:...:=***++-: .:-==*###**+**####*******+=-::...:-+**++=-. :-=+##*-:..:-+###+-:..:=*#*+-:..:=*#*=-: :=**+=-. :=++++-. :=+**+-. .-=+**+-...-=+##*-:.::-+##*=-:...-+***+=-. .:-=+*####*+==========++*###*+=-:. .-=+***+-...:-=*##+-::.:-*##+=-:..-+#*+=-. .-+**+=: .-++++=: :=+*+=: .-=+**=: :-+***=: .:-+*#*=:..:-+###+-::.:-+##*=-:. .-=++****+---::. .::::--+****++=-. .:-+*##+-::.:-+##*=-:..:=*#*+-: .=**++-. :=+*++-. :=+**+: -++*+=. :=+**+-. .-=+**+-..:-=*##+-..:-=*##+-::.:-+##*=-:. :=+++*++-:...:.. ...:.. .:-=+**#*=:..::-+##*+-:...-+#*+=-. -+**+=: .-++*+=: .-++*+=. :=+**+- =+**+- .-=+**=: :-=*#*=:..:-+*#*=:.::-+##*=::.:-+##*=-:. .-+**++=-: .::---====---:. .::-=*##*=-:...-+##+=-: :=+*++-. .=++++-. :=+**+-. .-=+**+: .:-=*#*= =+**=: :-=***=. .:=+*#+-..:-=*##+-..:-=*##+-:.::=*##+-:...-+**++=:. .:-==+*###*+++++=-:..:::=*##*=-:. .-+**+=: -=+*+=: .-=+**=: :-=*#*=. .:=+*#+-..:-=*##+ =+**=. .:=+**+-. .-=*##+:..:-+*#*=:.::-+##*-::::=*##+=::..-+##*=-: :-=++*###**+++*###*=-::. .-+**+=-. :=++*+=. :-+**+-. .:=+*#+-..:-=*##+:..:-+##*=:.::=*##+ +**+-. .-=+**+:..:-+*#*=:..:=+##+-:.:-=*##+-:.:-+##*=-:..:+*#*=-:. .:=++***+=------=+*##*+=-. .-++*+=: .-=+**+: .-=*#*=:..:-+*#*=:.::=*##+-:.:-+##*=::.:-*##+ +**+-. :-=*#*=:..:-+##*-..:-=*##+-:.:-+##*=::.:-*##+-:..:=*#*+-:. .-+**++=-:. ..:...:-=+*++=-. :-+***=. .:-+*#*-...:=+##+-..:-=*#*=::::-+##+-::.:=*#*=-:..-+##+ +*#+:..:-+*#*=:..:=*##+-:.:-+##*=::::-*##+-:..:=*#*=-:..:+##+=-. .:+**++-: .::::. :-++**+:. .-=+##+:..:-=*#*=:..:-+##*-::::=*##+-:.:-+##*=::.:=*#*+-:..:+##+ *##+:..:-+##*-:.::=*##+-:::-+##*=::.:=*##+-:..-+##*=-...-*#*+-:. .=***+-: :-====-: .:-+*#*=:..:-+##*-:.::=*##+-:.:-+##*=::.:=*##+-:..:+##+=-...-*#*+-:. :+**+ *##=:..:-+##*-:.::=*##=-:.:-+##+-:..:=*#*=-:..-+##+=:. :=*#*=-: :+**+=:. .-=++**#*+-..:-=*##+-:.:-+##*=::.:=*##+-:..:+##*=-:..-*#*+-:..:+**+=-. .-***+-: :=**+ *##=::::-+##+-::::=##*=-:.:-*##+-:..:=##*=-:..-+#*+-:. :=**+=-. .-+**+=: :=+*+++##*=::::=*##+-:.::+##*=-:.:-*##+-:..:+##*=-...-*#*+-: :=**+=-. .-+*++-. :=+*+ ##*=::.:-*##+-:..:=##*=-:..-*#*+-:..:=*#+=-. .-+**+-: :=**+=-. .-+*++=. :=++++*##*=::.:=*##+-:..:+##*=-:..-*#*+-:..:+**+=-. .-***+-: :=**+=: .-+*++-. :=+++ ##*=-:..-*##+-:..:=*#*=-...-+#*+-:. :=**+=-. .-+**+=: .=+*+=-. -=+*+=: .-=+*###*=-:..:=*#*=-:..-+##+=:...=*#*=-: :+**+=:. .-+*++-. :=**+=: .-++++-. :=+** ##*=-:..-+#*+-:. :=**+=-. .-+**+=: .=**+=-. :++++=: .-++*+-. :=+**+-. .:--=++=-:::.:-*##+=:...-*#*+-:. :=**+=-. -+**+=: .=+*+=-. :=+++=: .-++*+-. .-=+** *#*=-: .-+**+=:. .=**+=-. :+**+=: .-++++-. :=+**+: .-=+**=: :-=+##+-:...........::-+##*=-:..:=*#*=-. :+**+=:. .-+*++-. :=+*+=- .-++*+=. :=+**+- .-=+** ***=-. :+**+=: .-+*++-. :=+++=: .-=+*+=. :-+**+-. .:=+*#*-:..:-+*##*=--:. .:--=*##*=-:...-*#*+=:. .-+**+-: .=+*+=-. :=+*+=: .-++*+-. :=+**+: :-=*** +*++-. :=+*+=: .-++*+=. :=+**+-. .:=+**+: :-=*#*+:..:-=*##+-::.:-=*##*+==------==+*##*=-:...-+##+=-. :+**+=-. :++*+=: .-++*+=. :=+**+-. .-=+**=: .:-+*#* ++++=: :=++*+-. .:=+**=: .-=***=. .:-+*#*-...:=+##*=::::-+##*+-:.. .-++++**##***++**#*+-::..:-+##*=-:. .=***+=: .-+*++-. :=++*+-. .-=+**+: :-=*#*=. .:=+##+ =+*+=: .-++**=. .:=+**+-. .-=+##+-..:-=*##+-:.:-=*##+-:...-+##*+=:. .:-==+*###**++++=-:..:::=*##*=-:. .-+**+=:. :=+*+=: .-=+**=: .-=***=. .:=+*#+-..:-=*##+ =+**+-. .-=+**=:..:-+*#*=:..:-+##*=:.::-+##*=::..-+##*=-:. .-++*+++-: .::::--====--:. .::-+*##*=-:. .-+**+=-. :=+*++-. :=++*+-. .:=+**+-. .-=+##+:..:-+*#*= -+*#*=...:=+##+-..:-=*##+-:.:-=###+-:..:=*#*+-:. .-+**+=-. .:=++*#*+-:::.. .::.. .:--=+###*=-:...-+**+=-: .-+*++=: .-=+**=: .-=+**=: .:-+*#*=:..:=+##*- -=*##=:..:-+##*=::::-+##*=::..-*##+=-. .-+**+=-. .-++**+-. .:-=*###*+=--:.....:::..:--=++*##*+-::..:-+##*=-: .-+**+=-. :=+**+-. .:=+*#+-...-=+##+-..:-=*##+- :=*##+-::::=*##+-:..:=*#*=-:. :=***+-: .-++++=-. :-=+*#*=:..:::-=****++*+++======++********=-:..::-=*##*=-:. .-+**++-. .-++**=: :-=***=:..:-=*#*=:..:-+##*=: :-+##*=-:..-+##+=-. .-+**+=:. :++*++-. :-++**+-. .:-=*##*+--:. .:==++*####**++*####**++==:. .:--+###*=-:. .-+**++-: .-=+**+: .-=+*#+-...-=+##+-..:-=*##+-: .:=*#*=-:. :=**+=-: :=+*++-. .-=+**+:. .:-+*##+-:::::=+##*+=-:. .:--==+**++++****+==--: :--=*###+=-:...-+**++-: .-=+**+-. :-+***=:..:-+*#*=:..:-+##*=:: .-+**+=:. .-+**+=: .-=+**+-. .:-+*#*+:..::-+###+=-:. .:=+***++=-:........::-----::::::.. :-==+*##*=-::..:=*#*+=-: .:=++++-. :-=+**+:..:-=*##+-..:-=*##+-:: :=+*++-. :=++*+=. :-=***+-..::=+##*=-::.:-+*#*+=-: :-=+*###*+=--:. ..:. .:::::-=+++****=-:..::-=*##+=-:. .-=+*++=: .-=+**+-. .:=+##*=:.::-+##*=::. .-=+**=: .-=+**+-...:-+##*=-::::=*##*=-:. .:=+*+++=:. .::-=+*##**++==--::::::...::---=+**#**+++=:. ..:-=+###+=-:. .-+**++=: .-=+**+-. .:-+*#*=:..:-=*##+-::: . :-+***=:..:-=*##+-:.::=*##*=-:..:-+**+=-: :-=+*#*+=:::...:-=++++*###**++=+++++++++**###*+==-:. .:-=+*##*+-::...-+**++-: .:=+**+=. :-=*##+-..::=*##*-::.:

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.

Key takeaways

Are Analyst Price Targets Accurate? 7 Years of Data

How to Follow Wall Street Analysts the Smart Way: Track Records, Not Headlines

What Are Exent Gems? Top‑Analyst Agreement Explained